Evofem Biosciences, Inc.

Evofem Biosciences, Inc., a Delaware corporation (the “Company”), is unable to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2023 (the “Quarterly Report”) within the prescribed time-period without unreasonable effort or expense. The Company requires additional time to finalize certain of the disclosures in its Quarterly Report, as well as the financial statements to be filed as part of the Quarterly Report. The additional time is required to, among other things, incorporate information regarding changes to the Company’s business and capitalization structure during the three months ended March 31, 2023, to account for the recent changes to management, including the appointment of a new Chief Financial Officer. The Company requires the additional time to finalize the Quarterly Report to complete its financial reporting process with new management in place. For the foregoing reasons, the Company requires additional time to complete the procedures relating to its first quarter reporting process, including the completion of the Company’s financial statements, and therefore, the Company is unable to file the Quarterly Report by May 15, 2023, the prescribed filing due date for the Quarterly Report. The Company currently expects to file the Quarterly Report as soon as practicable, but the Company does not expect to file the Quarterly Report within the extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended

Evofem Biosciences, Inc., a Delaware corporation (the “Company”), is unable to file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”) within the prescribed time period without unreasonable effort or expense. The Company requires additional time to finalize certain of the disclosures in its Annual Report, as well as the financial statements to be filed as part of the Annual Report. The additional time is required to, among other things, incorporate information regarding changes to the Company’s business and capitalization structure during the year ended December 31, 2022, and to account for various transactions that were consummated by the Company during 2022. For the foregoing reasons, the Company requires additional time to complete the procedures relating to its year-end reporting process, including the completion of the Company’s financial statements, and therefore, the Company is unable to file the Annual Report by March 31, 2023, the prescribed filing due date for the Annual Report. The Company expects to file the Annual Report within the extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended

Evofem Biosciences, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 within the prescribed time period due to a lack of financial resources. The Company currently expects to file its Form 10-Q for the quarter ended September 30, 2022 as soon as practicable, but does not expect it will file within the prescribed time period pursuant to Rule 12b-25. Special Note Regarding Forward-Looking Statements This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties, including all statements regarding the Company’s expectation that it will file its Form 10-Q for the quarter ended September 30, 2022. Forward looking statements are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including but not limited to risks and uncertainties related to the Company’s resources. There can be no assurance that these forward-looking statements will be achieved, and actual results could differ materially from those suggested by such forward-looking statements